Interactive presentation

New Strategies for Individualizing Long-term Care

Mario Castro, MD, MPH; Reynold A. Panettieri, Jr., MD; Michael Wechsler, MD
Suggested Readings

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

Brightling CE, et al. Lancet Respir Med. 2015;3(9):692-701.

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

Bleecker ER, et al. Lancet. 2016;388(10056):2115-2127.

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

Castro M, et al. Lancet Respir Med. 2015;3(5):355-366

A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.

D’Amato G, et al. Ther Clin Risk Manag. 2007;3(4):613-619

Biologics in asthma—the next step toward personalized treatment.

Darveaux J, Busse WW. J Allergy Clin Immunol Pract. 2015;3(2):152-161.

Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations.

Denlinger LC, et al. Am J Respir Crit Care Med. 2017;195(3):302-313.

Targeting key proximal drivers of type 2 inflammation in disease

Gandhi NA, et al. Nat Rev Drug Discov. 2016;15(1):35-50.

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

FitzGerald JM, et al. Lancet. 2016;388(10056):2128-2141.

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

Hanania NA, et al. Lancet Respir Med. 2016;4(10):781-796

Adult asthma biomarkers.

Kim MA, et al. Curr Opin Allergy Clin Immunol. 2014;14(1):49-54.

Mepolizumab treatment in patients with severe eosinophilic asthma

Ortega HG, et al. N Engl J Med. 2015;371(13):1198-1207.

Allergen immunotherapy in asthma; what is new?

Passalacqua G, et al. Asthma Res Pract. 2015;1:6

Co-morbidities in severe asthma: clinical impact and management.

Porsbjerg C, Menzies-Gow, A. Respirology. 2017;22(4):651-661.

Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma.

Wechsler ME, et al. J Allergy Clin Immunol. 2013;132(6):1295-1302.e3.

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Wenzel S, et al. Lancet. 2016;388(10039):31-44

Linked Resources

eBook Reader

Guidelines

Global Strategy for Asthma Management and Prevention

Global Initiative for Asthma (GINA) 2017.

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Chung KF, et al. Eur Respir J. 2014;43(2):343-373.

Patient Resources

Asthma and Allergy Foundation of America (AAFA)

AAFA is dedicated to improving the quality of life for people with asthma and allergic diseases through education, advocacy, and research.

American College of Allergy, Asthma, and Immunology (ACAAI)

The ACAAI fosters a culture of collaboration and congeniality in which members work toward the common goals of patient care, education, advocacy, and research.

American College of CHEST Physicians (CHEST Foundation)

The mission of CHEST Foundation is to develop resources to champion the prevention, diagnosis, and treatment of chest diseases through education, communication, and research.

American Lung Association

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy, and research.

American Thoracic Society

The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders.

Asthma Action Plan

This printable reference tool is designed to help patients know when to use their different asthma medications and when to call their health care providers.

Clinical Assessment Tools

Asthma Control Test (ACT)

This 5-question test evaluates asthma control over the past 4 weeks on a 5-point Likert scale. A score of <20 on the ACT suggests asthma that is uncontrolled. Nathan RA, et al. J Allergy Clin Immunol. 2004;113(1):59-65.

Asthma Control Questionnaire (ACQ)

This 7-question assessment tool measures asthma control over the past 7 days. Six questions are self-administered by the patient, and 1 question requires a clinician’s input. Scores range from 1 (totally controlled) to 6 (severely uncontrolled. Juniper EF, et al. The Euro Respir J. 1999;14(4):902-907.

Asthma Therapy Assessment Questionnaire (ATAQ)

This 4-question test assesses asthma control over the past 4 weeks. Each question has a possible score of 0 or 1; if the sum of the 4 question scores is >1, the patient’s asthma may be uncontrolled. Vollmer WM, et al. Am J Crit Care Med. 1999;160(5 Pt 1):1647-1652.